Journal of clinical lipidology最新文献

英文中文

Obesity and statin intolerance: Implications for LDL-C target achievement in PCSK9 inhibitor therapy 肥胖和他汀类药物不耐受：PCSK9抑制剂治疗对LDL-C目标实现的影响

IF 4.6 3区医学 Q2 PHARMACOLOGY & PHARMACY

Journal of clinical lipidology

Pub Date : 2026-02-01 Epub Date: 2025-12-15 DOI: 10.1016/j.jacl.2025.10.056

Luca Bonanni MD

引用次数: 0

Epicardial fat thickness by transthoracic echocardiography as a predictor of obstructive coronary artery disease 经胸超声心动图心外膜脂肪厚度作为阻塞性冠状动脉疾病的预测因子

IF 4.6 3区医学 Q2 PHARMACOLOGY & PHARMACY

Journal of clinical lipidology

Pub Date : 2026-02-01 Epub Date: 2025-11-07 DOI: 10.1016/j.jacl.2025.10.070

Hela Bouzidi , Hakim Lamine , Ihsen Zairi , Alaeddine Ayadi , Ghassen Tlili , Khadija Mzoughi , Sondos Kraiem

BACKGROUND

Epicardial adipose tissue (EAT), a visceral fat depot with metabolic and inflammatory properties, has been increasingly recognized as a potential marker for coronary artery disease (CAD). However, its clinical utility and optimal cut-off values remain under investigation.

OBJECTIVE

To assess the association between 2D echocardiographic EAT thickness and the presence and severity of obstructive CAD, and to determine optimal EAT thresholds for predicting significant CAD.

METHODS

This cross-sectional study included 120 patients undergoing coronary angiography at a single tertiary center in Tunisia. EAT thickness was measured echocardiographically at end-systole and end-diastole in parasternal long- and short-axis views. CAD severity was evaluated using Syntax and Gensini scores. Patients were stratified into obstructive and non-obstructive CAD groups and further divided into tertiles based on EAT thickness.

RESULTS

Obstructive CAD was identified in 66.7% of patients. EAT thickness was significantly higher in those with obstructive CAD (diastolic: 3.29 ± 0.99 mm vs 2.15 ± 1.38 mm; systolic: 5.68 ± 1.36 mm vs 4.05 ± 1.88 mm; P < .001 for both). Diastolic EAT > 2.45 mm and systolic EAT > 4.4 mm were independent predictors of obstructive CAD (odds ratio = 3.37 and 10.57, respectively), with strong diagnostic performance (area under the curve: 0.83 and 0.82). EAT thickness also correlated positively with Gensini and Syntax scores (r ≈ 0.5, P < .001), and higher tertiles were associated with multivessel disease and calcification.

CONCLUSION

Echocardiographic EAT thickness is a reliable, noninvasive predictor of obstructive CAD and correlates with disease complexity. Given its simplicity and predictive value, it may serve as a useful screening tool for CAD severity stratification. Further large-scale studies are warranted to validate cut-off values and standardize assessment protocols.

背景：心外膜脂肪组织（EAT）是一种具有代谢和炎症特性的内脏脂肪库，已越来越多地被认为是冠状动脉疾病（CAD）的潜在标志物。然而，其临床应用和最佳临界值仍在研究中。目的：评估二维超声心动图EAT厚度与阻塞性CAD存在及严重程度的关系，并确定预测显著性CAD的最佳EAT阈值。方法：本横断面研究包括120例在突尼斯单一三级中心接受冠状动脉造影的患者。在胸骨旁长轴和短轴视图上，在收缩期末和舒张期末用超声心动图测量EAT厚度。使用Syntax和Gensini评分评估CAD严重程度。将患者分为梗阻性和非梗阻性CAD组，并根据EAT厚度进一步分为各组。结果：66.7%的患者诊断为阻塞性CAD。阻塞性CAD患者的EAT厚度显著增高（舒张期：3.29±0.99 mm vs 2.15±1.38 mm；收缩期：5.68±1.36 mm vs 4.05±1.88 mm；两者P < 0.001）。舒张期EAT > 2.45 mm和收缩期EAT > 4.4 mm是阻塞性CAD的独立预测因子（优势比分别为3.37和10.57），具有较强的诊断价值（曲线下面积：0.83和0.82）。EAT厚度也与Gensini和Syntax评分呈正相关（r≈0.5,P < .001），较高的分值与多血管疾病和钙化相关。结论：超声心动图EAT厚度是一种可靠的、无创的阻塞性CAD预测指标，并与疾病复杂性相关。由于其简单性和预测价值，它可以作为CAD严重程度分层的有用筛选工具。需要进一步的大规模研究来验证临界值和标准化评估方案。

{"title":"Epicardial fat thickness by transthoracic echocardiography as a predictor of obstructive coronary artery disease","authors":"Hela Bouzidi , Hakim Lamine , Ihsen Zairi , Alaeddine Ayadi , Ghassen Tlili , Khadija Mzoughi , Sondos Kraiem","doi":"10.1016/j.jacl.2025.10.070","DOIUrl":"10.1016/j.jacl.2025.10.070","url":null,"abstract":"<div><h3>BACKGROUND</h3><div>Epicardial adipose tissue (EAT), a visceral fat depot with metabolic and inflammatory properties, has been increasingly recognized as a potential marker for coronary artery disease (CAD). However, its clinical utility and optimal cut-off values remain under investigation.</div></div><div><h3>OBJECTIVE</h3><div>To assess the association between 2D echocardiographic EAT thickness and the presence and severity of obstructive CAD, and to determine optimal EAT thresholds for predicting significant CAD.</div></div><div><h3>METHODS</h3><div>This cross-sectional study included 120 patients undergoing coronary angiography at a single tertiary center in Tunisia. EAT thickness was measured echocardiographically at end-systole and end-diastole in parasternal long- and short-axis views. CAD severity was evaluated using Syntax and Gensini scores. Patients were stratified into obstructive and non-obstructive CAD groups and further divided into tertiles based on EAT thickness.</div></div><div><h3>RESULTS</h3><div>Obstructive CAD was identified in 66.7% of patients. EAT thickness was significantly higher in those with obstructive CAD (diastolic: 3.29 ± 0.99 mm vs 2.15 ± 1.38 mm; systolic: 5.68 ± 1.36 mm vs 4.05 ± 1.88 mm; <em>P</em> < .001 for both). Diastolic EAT > 2.45 mm and systolic EAT > 4.4 mm were independent predictors of obstructive CAD (odds ratio = 3.37 and 10.57, respectively), with strong diagnostic performance (area under the curve: 0.83 and 0.82). EAT thickness also correlated positively with Gensini and Syntax scores (<em>r</em> ≈ 0.5, <em>P</em> < .001), and higher tertiles were associated with multivessel disease and calcification.</div></div><div><h3>CONCLUSION</h3><div>Echocardiographic EAT thickness is a reliable, noninvasive predictor of obstructive CAD and correlates with disease complexity. Given its simplicity and predictive value, it may serve as a useful screening tool for CAD severity stratification. Further large-scale studies are warranted to validate cut-off values and standardize assessment protocols.</div></div>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":"20 2","pages":"Pages 368-377"},"PeriodicalIF":4.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145846676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reply to: “Obesity and statin intolerance: Implications for LDL-C target achievement in PCSK9 inhibitor therapy” 回复：“肥胖和他汀类药物不耐受：对PCSK9抑制剂治疗中LDL-C目标实现的影响”。

IF 4.6 3区医学 Q2 PHARMACOLOGY & PHARMACY

Journal of clinical lipidology

Pub Date : 2026-02-01 Epub Date: 2025-12-16 DOI: 10.1016/j.jacl.2025.12.014

Elena Formisano, Andrea Pasta, Livia Pisciotta

引用次数: 0

Lipid-lowering therapies to target cardiac allograft vasculopathy after heart transplantation: Current evidence and future directions 针对心脏移植后同种异体移植血管病变的降脂疗法：目前的证据和未来的方向。

IF 4.6 3区医学 Q2 PHARMACOLOGY & PHARMACY

Journal of clinical lipidology

Pub Date : 2026-02-01 Epub Date: 2025-12-04 DOI: 10.1016/j.jacl.2025.12.001

Taha Mansoor MD , Mahmoud Ismayl MBBS , Salim S. Virani MD, PhD , Vijay Nambi MD , Arunima Misra MD , Xiaoming Jia MD , Marat Fudim MD , Stephen J. Greene MD , Laurence Sperling MD , Sachin Parikh MD , Mahmoud Al Rifai MD , Santhosh KG Koshy MD, MBA , Dmitry Abramov MD , Abdul Mannan Khan Minhas MD

BACKGROUND

Heart transplantation represents an increasingly utilized procedure for end-stage heart failure patients.

CURRENT EVIDENCE

Cardiac allograft vasculopathy (CAV) is a post-transplant complication of pathological vasculature remodeling and remains an important cause for long-term graft failure and mortality. Current preventive strategies for CAV include optimization of vascular risk factors and pharmacotherapy with statins and immunosuppressants.

CONCLUSION

Despite demonstrated post-transplant mortality benefit and reduction in CAV with statins, the role of other pharmacotherapies on CAV reduction through low-density lipoprotein cholesterol (LDL-C) lowering remains less established. This review explores established evidence as well as evolving pathways for LDL-C lowering strategies to prevent CAV.

背景：心脏移植是终末期心力衰竭患者越来越多使用的一种治疗方法。目前证据：同种异体心脏移植血管病变（CAV）是一种病理性血管重构的移植后并发症，仍然是长期移植失败和死亡的重要原因。目前CAV的预防策略包括优化血管危险因素和他汀类药物和免疫抑制剂的药物治疗。结论：尽管移植后他汀类药物可降低患者的死亡率和CAV，但其他药物治疗通过降低LDL-C来降低CAV的作用仍然不太确定。本综述探讨了降低LDL-C策略预防CAV的既定证据和发展途径。

{"title":"Lipid-lowering therapies to target cardiac allograft vasculopathy after heart transplantation: Current evidence and future directions","authors":"Taha Mansoor MD , Mahmoud Ismayl MBBS , Salim S. Virani MD, PhD , Vijay Nambi MD , Arunima Misra MD , Xiaoming Jia MD , Marat Fudim MD , Stephen J. Greene MD , Laurence Sperling MD , Sachin Parikh MD , Mahmoud Al Rifai MD , Santhosh KG Koshy MD, MBA , Dmitry Abramov MD , Abdul Mannan Khan Minhas MD","doi":"10.1016/j.jacl.2025.12.001","DOIUrl":"10.1016/j.jacl.2025.12.001","url":null,"abstract":"<div><h3>BACKGROUND</h3><div>Heart transplantation represents an increasingly utilized procedure for end-stage heart failure patients.</div></div><div><h3>CURRENT EVIDENCE</h3><div>Cardiac allograft vasculopathy (CAV) is a post-transplant complication of pathological vasculature remodeling and remains an important cause for long-term graft failure and mortality. Current preventive strategies for CAV include optimization of vascular risk factors and pharmacotherapy with statins and immunosuppressants.</div></div><div><h3>CONCLUSION</h3><div>Despite demonstrated post-transplant mortality benefit and reduction in CAV with statins, the role of other pharmacotherapies on CAV reduction through low-density lipoprotein cholesterol (LDL-C) lowering remains less established. This review explores established evidence as well as evolving pathways for LDL-C lowering strategies to prevent CAV.</div></div>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":"20 2","pages":"Pages 262-269"},"PeriodicalIF":4.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145911867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pancreatitis in severe hypertriglyceridemia is a failure of temporal lipoprotein buffering: Not a problem of static lipid burden 严重高甘油三酯血症的胰腺炎是暂时性脂蛋白缓冲的失败：不是静态脂质负担的问题。

IF 4.6 3区医学 Q2 PHARMACOLOGY & PHARMACY

Journal of clinical lipidology

Pub Date : 2026-02-01 Epub Date: 2026-03-01 DOI: 10.1016/j.jacl.2025.12.012

Nav La, Schawanya K. Rattanapitoon, Chutharat Thanchonnang, Nathkapach K. Rattanapitoon

引用次数: 0

Ceramides and renal dysfunction in coronary artery disease: Promising biomarkers awaiting validation 神经酰胺和冠状动脉疾病的肾功能障碍：有前途的生物标志物等待验证。

IF 4.6 3区医学 Q2 PHARMACOLOGY & PHARMACY

Journal of clinical lipidology

Pub Date : 2026-02-01 Epub Date: 2026-03-01 DOI: 10.1016/j.jacl.2025.09.019

Muhammet Cihat Çelik MD , Mücahit Aker MD , Macit Kalçık MD

引用次数: 0

Improvement of severe hypertriglyceridemia in atypical subtype 4 partial lipodystrophy with volanesorsen volanesorsen改善非典型亚型4部分脂肪营养不良患者严重高甘油三酯血症。

IF 4.6 3区医学 Q2 PHARMACOLOGY & PHARMACY

Journal of clinical lipidology

Pub Date : 2026-02-01 Epub Date: 2025-12-01 DOI: 10.1016/j.jacl.2025.11.016

Pavla Jadrníčková MD , Lukáš Tichý PhD , Martina Kašpráková MD , Jan Václavík PhD, FESC , Tomáš Freiberger PhD

Lipodystrophic syndromes are a heterogeneous group of disorders characterized by a lack of fatty tissue or abnormal fat accumulation outside of the body’s typical fat distribution areas. Partial lipodystrophy most commonly manifests in childhood or young adulthood, and is classified into 6 primary subtypes, along with other rare categories. Lipodystrophy subtype 4 is associated with severe insulin resistance and unique traits, including severe hyperlipidemia, progressive liver disease, and arterial hypertension. Here we present the case of a 30-year-old woman with alarming hypertriglyceridemia, newly diagnosed diabetes mellitus, and severe hypertension. A complex differential diagnostic procedure yielded the diagnosis of familial partial lipodystrophy subtype 4. Initial treatment with plasmapheresis effectively reduced her triglyceride values but failed due to lack of intravenous access. Recurrent severe hypertriglyceridemia and normal leptin levels prompted the use of volanesorsen therapy, which is primarily indicated for treatment of hypertriglyceridemia in familial chylomicronemia syndrome. Volanesorsen proved very effective in this case.

脂肪营养不良综合征是一组异质性疾病，其特征是脂肪组织缺乏或身体典型脂肪分布区域外的异常脂肪堆积。部分脂肪营养不良最常见于儿童期或青年期，可分为6种主要亚型，以及其他罕见类型。脂肪营养不良亚型4与严重胰岛素抵抗和独特特征相关，包括严重高脂血症、进行性肝病和动脉高血压。在这里，我们提出的情况下，一个30岁的妇女报警高甘油三酯血症，新诊断的糖尿病，和严重的高血压。一个复杂的鉴别诊断程序产生了家族性部分脂肪营养不良亚型4的诊断。最初的血浆置换治疗有效地降低了她的甘油三酯值，但由于缺乏静脉通路而失败。复发性严重高甘油三酯血症和正常瘦素水平促使使用volanesorsen治疗，它主要用于治疗家族性乳糜低血症综合征的高甘油三酯血症。Volanesorsen在这种情况下被证明非常有效。

{"title":"Improvement of severe hypertriglyceridemia in atypical subtype 4 partial lipodystrophy with volanesorsen","authors":"Pavla Jadrníčková MD , Lukáš Tichý PhD , Martina Kašpráková MD , Jan Václavík PhD, FESC , Tomáš Freiberger PhD","doi":"10.1016/j.jacl.2025.11.016","DOIUrl":"10.1016/j.jacl.2025.11.016","url":null,"abstract":"<div><div>Lipodystrophic syndromes are a heterogeneous group of disorders characterized by a lack of fatty tissue or abnormal fat accumulation outside of the body’s typical fat distribution areas. Partial lipodystrophy most commonly manifests in childhood or young adulthood, and is classified into 6 primary subtypes, along with other rare categories. Lipodystrophy subtype 4 is associated with severe insulin resistance and unique traits, including severe hyperlipidemia, progressive liver disease, and arterial hypertension. Here we present the case of a 30-year-old woman with alarming hypertriglyceridemia, newly diagnosed diabetes mellitus, and severe hypertension. A complex differential diagnostic procedure yielded the diagnosis of familial partial lipodystrophy subtype 4. Initial treatment with plasmapheresis effectively reduced her triglyceride values but failed due to lack of intravenous access. Recurrent severe hypertriglyceridemia and normal leptin levels prompted the use of volanesorsen therapy, which is primarily indicated for treatment of hypertriglyceridemia in familial chylomicronemia syndrome. Volanesorsen proved very effective in this case.</div></div>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":"20 2","pages":"Pages 444-450"},"PeriodicalIF":4.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145944212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From the Editors: Update on Diagnosis and Treatment of Familial Hypercholesterolemia 来自编辑：家族性高胆固醇血症的诊断和治疗的最新进展。

IF 4.6 3区医学 Q2 PHARMACOLOGY & PHARMACY

Journal of clinical lipidology

Pub Date : 2026-02-01 Epub Date: 2026-03-01 DOI: 10.1016/j.jacl.2026.02.005

P. Barton Duell MD, MNLA , Kevin C. Maki PhD, MNLA

引用次数: 0

Precision approach in apoA-I infusion trials: When CSL112 may actually work apoA-I输注试验的精确方法：CSL112何时可能真正起作用。

IF 4.6 3区医学 Q2 PHARMACOLOGY & PHARMACY

Journal of clinical lipidology

Pub Date : 2026-02-01 Epub Date: 2025-12-17 DOI: 10.1016/j.jacl.2025.12.015

Vignesh Chidambaram MD, MPH , Amudha Kumar MD , Thorsten M. Leucker MD, PhD

In the recent ApoA-I Event Reducing in Ischemic Syndromes II trial, a plasma-derived apolipoprotein A-I (apoA-I) infusion (CSL112) demonstrated no significant reduction in major cardiovascular events in the overall postmyocardial infarction population. However, exploratory analyses revealed benefits in subgroups with both elevated low-density lipoprotein cholesterol (LDL-C) and systemic inflammation, suggesting that biologic context may be critical to therapeutic efficacy. Building on these trial findings, we highlight that the efficacy of CSL112 may depend on the coexistence of elevated LDL-C and systemic inflammation. We integrate ATP-binding cassette transporter A1 (ABCA1) biology with subgroup trial findings to propose a precision-stratification framework for future apoA-I infusion trials. We focus on the interaction of lipid burden and inflammation on ABCA1 transporter function, the impact of statin-induced transporter downregulation, and strategies for patient selection, including ex vivo efflux assays and molecular transporter profiling, and the therapeutic promise of combination therapies (apoA-I infusion with liver X receptor agonists) in patients with impaired transporter function.

在最近的ApoA-I事件减少缺血性综合征II的试验中，血浆源性载脂蛋白a- i （ApoA-I）输注（CSL112）显示，在心肌梗死后总体人群中，主要心血管事件没有显著减少。然而，探索性分析显示，低密度脂蛋白胆固醇（LDL-C）升高和全身性炎症的亚组都有益处，这表明生物学背景可能对治疗效果至关重要。基于这些试验结果，我们强调CSL112的疗效可能取决于LDL-C升高和全身性炎症的共存。我们将atp结合盒转运蛋白A1 （ABCA1）生物学与亚组试验结果结合起来，为未来的apoA-I输注试验提出了一个精确的分层框架。我们关注脂质负荷和炎症对ABCA1转运蛋白功能的相互作用，他汀类药物诱导的转运蛋白下调的影响，以及患者选择策略，包括体外排出试验和分子转运蛋白分析，以及转运蛋白功能受损患者联合治疗（apoA-I输注肝X受体激动剂）的治疗前景。

{"title":"Precision approach in apoA-I infusion trials: When CSL112 may actually work","authors":"Vignesh Chidambaram MD, MPH , Amudha Kumar MD , Thorsten M. Leucker MD, PhD","doi":"10.1016/j.jacl.2025.12.015","DOIUrl":"10.1016/j.jacl.2025.12.015","url":null,"abstract":"<div><div>In the recent ApoA-I Event Reducing in Ischemic Syndromes II trial, a plasma-derived apolipoprotein A-I (apoA-I) infusion (CSL112) demonstrated no significant reduction in major cardiovascular events in the overall postmyocardial infarction population. However, exploratory analyses revealed benefits in subgroups with both elevated low-density lipoprotein cholesterol (LDL-C) and systemic inflammation, suggesting that biologic context may be critical to therapeutic efficacy. Building on these trial findings, we highlight that the efficacy of CSL112 may depend on the coexistence of elevated LDL-C and systemic inflammation. We integrate ATP-binding cassette transporter A1 (ABCA1) biology with subgroup trial findings to propose a precision-stratification framework for future apoA-I infusion trials. We focus on the interaction of lipid burden and inflammation on ABCA1 transporter function, the impact of statin-induced transporter downregulation, and strategies for patient selection, including <em>ex vivo</em> efflux assays and molecular transporter profiling, and the therapeutic promise of combination therapies (apoA-I infusion with liver X receptor agonists) in patients with impaired transporter function.</div></div>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":"20 2","pages":"Pages 433-437"},"PeriodicalIF":4.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145989422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

JCL roundtable: European perspective on comprehensive lipid management and cardiovascular health JCL圆桌会议：欧洲对全面脂质管理和心血管健康的看法。

IF 4.6 3区医学 Q2 PHARMACOLOGY & PHARMACY

Journal of clinical lipidology

Pub Date : 2026-02-01 Epub Date: 2025-11-11 DOI: 10.1016/j.jacl.2025.11.006

Børge G. Nordestgaard MD, DMSc , Kausik K. Ray MD, FMedSci , P. Barton Duell MD

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of clinical lipidology

全部 Geobiology Appl. Clay Sci. Geochim. Cosmochim. Acta J. Hydrol. Org. Geochem. Carbon Balance Manage. Contrib. Mineral. Petrol. Int. J. Biometeorol. IZV-PHYS SOLID EART+ J. Atmos. Chem. Acta Oceanolog. Sin. Acta Geophys. ACTA GEOL POL ACTA PETROL SIN ACTA GEOL SIN-ENGL AAPG Bull. Acta Geochimica Adv. Atmos. Sci. Adv. Meteorol. Am. J. Phys. Anthropol. Am. J. Sci. Am. Mineral. Annu. Rev. Earth Planet. Sci. Appl. Geochem. Aquat. Geochem. Ann. Glaciol. Archaeol. Anthropol. Sci. ARCHAEOMETRY ARCT ANTARCT ALP RES Asia-Pac. J. Atmos. Sci. ATMOSPHERE-BASEL Atmos. Res. Aust. J. Earth Sci. Atmos. Chem. Phys. Atmos. Meas. Tech. Basin Res. Big Earth Data BIOGEOSCIENCES Geostand. Geoanal. Res. GEOLOGY Geosci. J. Geochem. J. Geochem. Trans. Geosci. Front. Geol. Ore Deposits Global Biogeochem. Cycles Gondwana Res. Geochem. Int. Geol. J. Geophys. Prospect. Geosci. Model Dev. GEOL BELG GROUNDWATER Hydrogeol. J. Hydrol. Earth Syst. Sci. Hydrol. Processes Int. J. Climatol. Int. J. Earth Sci. Int. Geol. Rev. Int. J. Disaster Risk Reduct. Int. J. Geomech. Int. J. Geog. Inf. Sci. Isl. Arc J. Afr. Earth. Sci. J. Adv. Model. Earth Syst. J APPL METEOROL CLIM J. Atmos. Oceanic Technol. J. Atmos. Sol. Terr. Phys. J. Clim. J. Earth Sci. J. Earth Syst. Sci. J. Environ. Eng. Geophys. J. Geog. Sci. Mineral. Mag. Miner. Deposita Mon. Weather Rev. Nat. Hazards Earth Syst. Sci. Nat. Clim. Change Nat. Geosci. Ocean Dyn. Ocean and Coastal Research npj Clim. Atmos. Sci. Ocean Modell. Ocean Sci. Ore Geol. Rev. OCEAN SCI J Paleontol. J. PALAEOGEOGR PALAEOCL PERIOD MINERAL PETROLOGY+ Phys. Chem. Miner. Polar Sci. Prog. Oceanogr. Quat. Sci. Rev. Q. J. Eng. Geol. Hydrogeol. RADIOCARBON Pure Appl. Geophys. Resour. Geol. Rev. Geophys. Sediment. Geol.

﹀